(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.86%) $83.13
(-1.16%) $1.619
(-0.45%) $2 336.60
(0.85%) $27.49
(0.48%) $926.50
(-0.20%) $0.933
(-0.21%) $11.00
(-0.26%) $0.798
(0.00%) $92.17
Live Chart Being Loaded With Signals
Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others...
Stats | |
---|---|
今日成交量 | 13.82M |
平均成交量 | 19.14M |
市值 | 23.05B |
EPS | CNY0.0600 ( 2023-10-25 ) |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | 92.31 |
ATR14 | CNY0.0270 (0.18%) |
音量 相关性
Walvax Biotechnology Co., 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Walvax Biotechnology Co., 相关性 - 货币/商品
Walvax Biotechnology Co., 财务报表
Annual | 2023 |
营收: | CNY4.08B |
毛利润: | CNY3.40B (83.25 %) |
EPS: | CNY0.260 |
FY | 2023 |
营收: | CNY4.08B |
毛利润: | CNY3.40B (83.25 %) |
EPS: | CNY0.260 |
FY | 2022 |
营收: | CNY5.09B |
毛利润: | CNY4.48B (88.02 %) |
EPS: | CNY0.460 |
FY | 2021 |
营收: | CNY3.46B |
毛利润: | CNY3.07B (88.61 %) |
EPS: | CNY0.273 |
Financial Reports:
No articles found.
Walvax Biotechnology Co.,
Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium Neisseria meningitidis group A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y, and W135. The company also offers haemophilus influenzae type b conjugate vaccine for children from the age of 2 months to 5 years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis for individuals from the age of 3 months to 6 years; and 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。